Crosstalk between m6A modification and alternative splicing during cancer progression
Clinical and Translational Medicine · 2023-10 · 13 (10)
DOI: 10.1002/ctm2.1460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 18.10.2023. Verfasst von Zhi-Man Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Alternative Splicing, Neoplasms. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
N6‐methyladenosine (m6A), the most prevalent internal mRNA modification in eukaryotes, is added by m6A methyltransferases, removed by m6A demethylases and recognised by m6A‐binding proteins. This modification significantly influences carious facets of RNA metabolism and plays a pivotal role in cellular and physiological processes. Main body Pre‐mRNA alternative splicing, a process that generates multiple splice isoforms from multi‐exon genes, contributes significantly to the protein diversity in mammals. Moreover, the presence of crosstalk between m6A modification and alternative splicing, with m6A modifications on pre‐mRNAs exerting regulatory control, has been established. The m6A modification modulates alternative splicing patterns by recruiting specific RNA‐binding proteins (RBPs) that regulate alternative splicing or by directly influencing the interaction between RBPs and their target RNAs. Conversely, alternative splicing can impact the deposition or recognition of m6A modification on mRNAs. The integration of m6A modifications has expanded the scope of therapeutic strategies for cancer treatment, while alternative splicing offers novel insights into the mechanistic role of m6A methylation in cancer initiation and progression.
Conclusion
This review aims to highlight the biological functions of alternative splicing of m6A modification machinery and its implications in tumourigenesis. Furthermore, we discuss the clinical relevance of understanding m6A‐dependent alternative splicing in tumour therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Respiratory Medicine, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Orthopedics, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Dong-Sheng Pei
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhu, Z. M., Huo, F. C., Zhang, J., Shan, H. J., & Pei, D. S. (2023). Crosstalk between m6A modification and alternative splicing during cancer progression. Clinical and Translational Medicine, 13(10). https://doi.org/10.1002/ctm2.1460
Vancouver
Zhu ZM, Huo FC, Zhang J, Shan HJ, Pei DS. Crosstalk between m6A modification and alternative splicing during cancer progression. Clinical and Translational Medicine. 2023;13(10). doi:10.1002/ctm2.1460
BibTeX
@article{Zhu2023,
author = {Zhu, Zhi-Man and Huo, Fu-Chun and Zhang, Jian and Shan, Hong-Jian and Pei, Dong-Sheng},
title = {Crosstalk between m6A modification and alternative splicing during cancer progression},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {10},
doi = {10.1002/ctm2.1460}
}
EUVIMED